A Phase 2 interventional study of Z-338 in Functional Dyspepsia, sponsored by Zeria Pharmaceutical. Completed at 1 site in Belgium. Open to participants aged 18 Years to 70 Years. Per ClinicalTrials.gov, last updated 2015-05-28.
Sponsored by Zeria Pharmaceutical · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 11 studies testing Z 338 in Dyspepsia — 1 open to participants now, 1 under way, none of them phase 3. Z 338 · Dyspepsia.
Among the 11 studies testing Z 338 in Dyspepsia, this one is the 6th largest by planned enrollment, is one of 3 that started in 2006, is one of 5 in phase 2, and was the 3rd registered.
372 studies on the registry are indexed under Dyspepsia; 66 are open to participants now.
Browse Dyspepsia studies →1 of the 11 studies testing Z 338 in Dyspepsia is open now. Recruiting first, the newest first:
Aga Khan University
Ages 18–70
No approval found in the FDA or EMA files read. How studies give it is on its page →
Of the 46 Dyspepsia studies recruiting now, 16 (35%) set no upper age limit and 23 (50%) stop at 75 or younger; 2 take children under 18; 8 take healthy volunteers.
This study: 18 Years to 70 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
11 studies; the count open now beside each. This study's row is marked.
First in 2004; this study’s year is marked. 3 started in 2006.
This study's planned enrollment of 282 is above the median of 89 across 302 interventional studies indexed under Dyspepsia.
Median enrollment 282 across the 11 interventional studies. Of the 10 that completed or were terminated, 0 (0%) have results posted.
This tab as a report to print or save as PDF → With an account.
10 of 11 have an industry lead sponsor. The 3 most frequent:
Zeria Pharmaceutical is the lead sponsor of 23 studies on the registry; none are open to participants now.
Zeria Pharmaceutical has 7 studies filed under Dyspepsia — fewer than ten, so there is no comparison to draw.
1 of the studies testing Z 338 in Dyspepsia that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07449689Aga Khan UniversityComparing Acotiamide and Itopride for the Management of Indigestion | 2026-12 |
Add it to your calendar (.ics) → With an account.
Among the 11 studies testing Z 338 in Dyspepsia, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
To evaluate the efficacy and safety of Z-338 in subjects with Functional Dyspepsia
Exclusion Criteria:
-
Global subject Outcome Assessment
Time frame: 12 month
Individual symptom
Time frame: 12 month
The record gives a start of Apr 2006, a primary completion of Apr 2009 and a completion of Oct 2009. It does not say whether these dates are actual or estimated.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in May 2015. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Z 338